02:20:24 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-02-28 Bokslutskommuniké 2022
2023-02-09 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning RLS 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-07-16 Kvartalsrapport 2021-Q2
2021-06-17 Årsstämma 2021
2021-05-27 Ordinarie utdelning RLS 0.00 SEK
2021-05-07 Kvartalsrapport 2021-Q1
2021-02-10 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-27 Ordinarie utdelning RLS 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-15 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-19 Extra Bolagsstämma 2019
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning RLS 0.00 SEK
2019-05-29 Årsstämma 2019
2019-05-15 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2018-11-30 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-06-14 Ordinarie utdelning RLS 0.00 SEK
2018-06-13 Årsstämma 2018
2018-05-31 Kvartalsrapport 2018-Q1
2018-02-28 Bokslutskommuniké 2017
2017-11-28 Kvartalsrapport 2017-Q3
2017-11-15 Extra Bolagsstämma 2017
2017-08-31 Kvartalsrapport 2017-Q2
2017-06-09 Ordinarie utdelning RLS 0.00 SEK
2017-06-08 Årsstämma 2017
2017-05-31 Kvartalsrapport 2017-Q1
2017-02-20 Bokslutskommuniké 2016
2016-11-30 Kvartalsrapport 2016-Q3
2016-08-31 Kvartalsrapport 2016-Q2
2016-06-01 Ordinarie utdelning RLS 0.00 SEK
2016-05-31 Årsstämma 2016
2016-05-31 Kvartalsrapport 2016-Q1
2016-02-29 Bokslutskommuniké 2015
2016-01-21 Extra Bolagsstämma 2016
2015-11-30 Kvartalsrapport 2015-Q3
2015-08-31 Kvartalsrapport 2015-Q2
2015-06-12 Ordinarie utdelning RLS 0.00 SEK
2015-06-11 Årsstämma 2015
2015-05-28 Kvartalsrapport 2015-Q1
2015-02-27 Bokslutskommuniké 2014
2014-11-28 Kvartalsrapport 2014-Q3
2014-09-12 Extra Bolagsstämma 2014
2014-08-29 Kvartalsrapport 2014-Q2
2014-06-10 Ordinarie utdelning RLS 0.00 SEK
2014-06-09 Årsstämma 2014
2014-05-23 Kvartalsrapport 2014-Q1
2014-03-05 Bokslutskommuniké 2013
2013-11-29 Kvartalsrapport 2013-Q3
2013-09-04 Kvartalsrapport 2013-Q2
2013-05-31 Kvartalsrapport 2013-Q1
2013-05-08 Split RLS 10:1
2013-04-11 Ordinarie utdelning RLS 0.00 SEK
2013-04-10 Årsstämma 2013
2013-03-05 Bokslutskommuniké 2012
2012-11-26 Kvartalsrapport 2012-Q3
2012-08-31 Kvartalsrapport 2012-Q2
2012-06-12 Ordinarie utdelning RLS 0.00 SEK
2012-06-11 Årsstämma 2012

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
RLS Global är verksamma inom bioteknik. Bolaget utvecklar biokemiska produkter och metoder för behandling av förekommande sår hos patienter. Bolagets produkter angriper skadad vävnad via den egenutvecklade teknologin som baseras på hypoklorit. Idag bedrivs forskning och utveckling inom vävnadsbaserad teknik. Bolaget har sitt huvudkontor i Göteborg.
2022-05-30 08:30:00

RLS Global strengthens its presence in the Middle East. Through a regional agent, Med Surg, the company will establish a local distribution network in Egypt, Saudi Arabia, Iraq, Lebanon, Qatar, the United Arab Emirates, Oman and Jordan.

The fact that RLS Global is establishing a network for the distribution of ChloraSolv, is an important step to obtain regulatory approval in the eight countries. The regulatory processes are estimated to take about three to twelve months, depending on the country. As soon as ChloraSolv is regulatory approved in a specific country, the commercial process starts.

The agreement with the regional agent Med Surg provides RLS Global with the opportunity for a strong presence, through the support of distributors who are each a major player in each country, throughout the Middle East. All distributors have well developed networks and extensive experience of products in advanced wound care. RLS Global will work with local major distributors such as Trios Care, Quadri Pharma, East one Medical, Plus Medical etc. RLS global has signed a 5-year agreement with Med Surg with the possibility of extension. The local distributors provide ChloraSolv at a fix price with a final customer price of approximately 400 SEK/treatment.

"We are now creating new revenue streams for ChloraSolv. This is an important step forward, completely in line with our strategy to enter the global market", says Karin Fischer, CEO of RLS Global. "A robust distribution network is crucial for the development of our business. Med Surg has a long and solid experience in the region within advanced wound care and is RLS Global's partner to ensure a successful launch and penetration of ChoraSolv in these countries".

"We are very pleased to enter this strategic transaction with RLS Global," said Hesham Elbakr, CEO of Med Surg. "We expect ChloraSolv to be an important treatment option for patients in need in the Middle East."

ChloraSolv is a unique product used in the debridement of wounds with indications for diabetic foot ulcers and venous leg ulcers. There are approximately 81 million diabetic patients in the entire Middle East and the prevalence is expected to increase by 2045 according to the International Diabetes Federation (International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: 2019 (https://www.diabetesatlas.org/en/)). The prevalence of diabetic foot ulcers is 7.2%.

"ChloraSolv with its unique properties will help many patients who are suffering greatly due to diabetes. It is also a patient group that is responsible for high health care costs", says Karin Fischer. "We have been in contact with a number of key option leaders in the area who have already gained experience with ChloraSolv and are interested in being able to start treating patients with the product."

RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the above contact person, 30-05-2022 08:30 CET.